Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate (Q34547313)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

age related macular degeneration

1 reference

based on heuristic

inferred from title

author name string

Mohamed A Ibrahim

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Diana V Do

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Yasir J Sepah

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Syed M Shah

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Elizabeth Van Anden

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gulnar Hafiz

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

J Kevin Donahue

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Richard Rivers

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jai Balkissoon

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

James T Handa

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Peter A Campochiaro

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Quan Dong Nguyen

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

14 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

BMC pharmacology & toxicology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Absolute blood velocity measured with a modified fundus camera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Differentiation and definition of vascular-targeted therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Targeting tumour vasculature: the development of combretastatin A4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

7 July 2018

Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-7

21 January 2018

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-7

21 January 2018

Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study.

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-7

21 January 2018

Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-7

21 January 2018

Photoreceptor outer segment abnormalities as a cause of blind spot enlargement in acute zonal occult outer retinopathy-complex diseases

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-7

21 January 2018

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

1 reference

https://api.crossref.org/works/10.1186%2F2050-6511-14-7

21 January 2018

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552984

27 October 2018

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23316779

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/2050-6511-14-7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dimensions Publication ID

0 references

release_y4c2lqcdsre3tm2fujntwfxgsi

1 reference

https://api.fatcat.wiki/v0/release/y4c2lqcdsre3tm2fujntwfxgsi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34547313&oldid=2196765984"